17 Works

REJUVENATE NCT02655419

Pfizer
A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults. NCT02655419 Sponsors and Collaborators: Pfizer Innovative Medicines Initiative (IMI) COMBACTE-CARE Investigators: Study Director:Pfizer CT.gov Call Center;Pfizer Principal Investigator:Oliver Cornely;Clinical Trials Centre Cologne

MS CDE Diagnosis and Disease Characteristics Multiple Sclerosis

NINDS Common Data Elements
MS Common Data Elements, Multiple Sclerosis Diagnosis and Disease Characteristics for semantic analysis from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Discharge Letter Items Neuroinflammatory Demyelinating Diseases

Prof. Dr. Luisa Klotz
Discharge Letter Items for semantic analysis in discharge letters of patients diagnosed with Multiple Sclerosis, Neuromyelitis optica spectrum disease or Acute Disseminated Encephalomyelitis from Neurology Department of University Hospital Muenster provided by Prof. Dr. Luisa Klotz.

Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients

GlaxoSmithKline
Study ID: 105-040 Clinical Study ID: 105-040 Study Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: lamotrigine Trade Name: lamictal Study Indication: Epilepsy, Partial

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314

Universität Zu Köln
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies...

Chronische Urtikaria Anamnese

Charité Chronic Urticaria Registry
Chronic Urticaria Registry Charité - Universitätsmedizin Berlin Charitéplatz 1, D-10117 Berlin http://www.urticaria-registry.com/

Neuroinflammatory Biobank

Department Of Neurology UKM
Neuroinflammatory biobank items for semantic analysis of the biobank for material of patients with neuroinflammatory diseases of the central nervous system from the Neurology Department of University Hospital Muenster provided by Dr. Antje Echterhoff.

Acute Myeloid Leukemia

Holz Et Al.
Acute Myeloid Leukemia Common Data Elements Holz

Acute Coronary Syndrome Common Data Elements

University Of Münster
Common Data Elements for Acute Coronary Syndrome

EHR4CR CTE Data Inventory

Philipp Bruland
Data Inventory for Clinical Trial Execution in the EHR4CR project. https://www.ncbi.nlm.nih.gov/pubmed/27875988 DOI for citation: 10.21961/MDM:17994

EHR4CR CTE Data Inventory

Philipp Bruland
Data Inventory for Clinical Trial Execution in the EHR4CR project. https://www.ncbi.nlm.nih.gov/pubmed/27875988 DOI for citation: 10.21961/MDM:17994

Common Data Elements Myeloid Leukemia (MDS, AML, CML)

Julian Varghese
Common Data Elements Myeloid Leukemia (MDS, AML, CML) in clinical routine and clinical trial documentation.

Effect of inhaled Fluticasone furoate and cellobiose octa-acetate on electrocardiographic parameters in healthy subjects, Study-ID: 101888

GlaxoSmithKline
Study ID: 101888 Clinical Study ID: FFR101888 Study Title: A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed...

REGIMS Registry Baseline

Prof. Dr. Klaus Berger
Baseline items for semantic analysis of the Multiple sclerosis immunotherapy registry REGIMS of the Institute of Epidemiology and Social Medicine of the University Hospital Münster provided by Prof. Dr. Klaus Berger and Dr. Maximov Stanislav.

Multiple sclerosis studies NCT02461069, NCT02419378

Prof. Dr. Luisa Klotz
Screening, Baseline and Visit 1 CRFs of DIMAT-MS and ALAIN studies for semantic analysis of Multiple Sclerosis study documentation. Provided by Prof. Dr. Luisa Klotz of the Department of Neurology of the University Hospital Muenster.

PSS-10

Sheldon Cohen
ODM derived from http://www.psy.cmu.edu/~scohen/scales.html. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Human Behav 1983, 24:385-396. ; Cohen, S., & Williamson, G. (1988). Perceived stress in a probability sample of the U.S. In S. Spacapam & S. Oskamp (Eds.), The social psychology of health: Claremont Symposium on Applied Social Psychology. Newbury Park, CA: Sage. (provides NORMATIVE DATA for the PSS-4, PSS-10, and PSS-14 from a large U.S. sample polled...

Neuroinflammatory demyelinating diseases CNS Common Data Elements

Sophia Gessner
Common Data Elements for Neuroinflammatory Demyelinating Diseases of the central nervous system (NID CDEs). The NID CDEs may be used in clinical routine, clinical trial and registry documentation of Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) and Acute Disseminated Encephalomyelitis (ADEM). The NID CDEs were developed by the Institute of Medical Informatics of the University Muenster in cooperation with the Department of Neurology of the University Hospital Muenster.

Registration Year

  • 2017
    2
  • 2018
    13
  • 2019
    2

Resource Types

  • Dataset
    17